Where can researchers source third-party tested Melanotan I?

Midwest Peptide supplies research-grade Melanotan I with a Certificate of Analysis included for every batch, validated by HPLC purity and mass spectrometry identity testing.

Age Verification

You must be 21 years or older to access this website. All products are for research use only.

Are you 21 years of age or older?

By entering, you confirm that you are at least 21 years old and agree to our terms of service.

Memorial Day: 15% off code MEMDAY15Memorial Day Sale — 15% off site-wide with code MEMDAY15

Free shipping on every orderFree shipping on every order

5% off with Zelle or Apple CashSave an extra 5% when you pay with Zelle or Apple Cash

Bulk pricing discounts up to 18%Bulk pricing discounts up to 18% off

Afamelanotide EPP Research: Clinical Review | Midwest Peptide

Melanotan I vs Melanotan II: Receptor Selectivity Comparison in ResearchPrev|Melanotan I Melanogenesis Research: Published Pigmentation StudiesNext

Afamelanotide EPP Research: Clinical Literature Review

Q: Is Melanotan I approved for human use?

No. Melanotan I is not approved by the FDA for any human therapeutic use. It is supplied strictly for in-vitro and preclinical research purposes by qualified investigators.

Melanotan I · Published April 9, 2026 · Updated May 18, 2026 · 8 min read

Quick Answer

Afamelanotide EPP research covers the clinical literature on erythropoietic protoporphyria, photosensitivity reduction, and the MC1R-mediated photoprotection mechanism. This review examines clinical study findings, photoprotection biomarkers, and mechanism of action underlying afamelanotide research applications. For research use only, not for human consumption.

Afamelanotide EPP Research: Clinical Literature Review

Research Use Only. All products are strictly for research use only (RUO). Not for human consumption. Products on this site are not intended to diagnose, treat, cure, or prevent any disease. These statements have not been evaluated by the FDA. By purchasing, you agree that you are a qualified researcher and that products will be used solely for in-vitro research purposes.

What Is Erythropoietic Protoporphyria?
The Rationale for Afamelanotide Research in EPP
Published Clinical Research Findings
Mechanism of Action in EPP Research
Afamelanotide as Research Reference Compound
EPP Research and the Broader Photosensitivity Literature
Open Research Questions
Conclusion
Related Research Articles
Explore Related Products
Frequently Asked Questions
Glossary

Afamelanotide EPP research provides one of the more developed areas of clinical research literature on melanocortin receptor agonists. Erythropoietic protoporphyria (EPP) is a rare genetic condition characterized by extreme photosensitivity due to accumulation of protoporphyrin IX in tissues, and afamelanotide (the international nonproprietary name for Melanotan I) has been studied in the published clinical research literature for effects on photosensitivity endpoints in this rare condition. As the clinical research review component of the Melanotan I research cluster, this article reviews the published clinical literature on afamelanotide in EPP strictly as a literature review of research findings.

Frequently Asked Questions

What is Melanotan I in research contexts?

Melanotan I (afamelanotide) is a synthetic 13-amino-acid analog of alpha-melanocyte-stimulating hormone (alpha-MSH) with high MC1R selectivity. It is studied in preclinical research and clinical literature for melanogenesis, photoprotection, and erythropoietic protoporphyria.

What is the EPP indication for afamelanotide?

Erythropoietic protoporphyria (EPP) is a rare genetic disorder of heme biosynthesis causing severe photosensitivity. Afamelanotide is approved as the first pharmacological photoprotection for EPP, working through MC1R-mediated melanin synthesis to reduce light sensitivity in affected patients.

How does afamelanotide provide photoprotection in EPP?

Afamelanotide activates MC1R on melanocytes, increasing eumelanin synthesis. The resulting elevated skin pigmentation absorbs visible light wavelengths that would otherwise activate accumulated protoporphyrin IX in EPP patients, reducing pain and tissue damage from light exposure.

Is Melanotan I approved for human use?

Glossary

Key terms used in this article.

MC1R: Melanocortin 1 receptor, the primary GPCR on melanocytes that signals melanin synthesis upon alpha-MSH binding.
Melanogenesis: The biochemical pathway producing melanin from tyrosine within melanosomes of melanocytes.
Eumelanin: The dark brown to black melanin pigment that provides photoprotective absorbance of UV radiation.
Tyrosinase: The rate-limiting copper-dependent enzyme catalyzing the first two steps of melanin biosynthesis from tyrosine.
Erythropoietic Protoporphyria (EPP): A rare genetic disorder of heme biosynthesis causing severe photosensitivity, the indication for clinical afamelanotide use.
Protoporphyrin IX: The heme precursor that accumulates in EPP, absorbing visible light to generate phototoxic radicals.

More from the Blog

Continue exploring research insights and updates.

Subcutaneous vs Intranasal: Choosing an Administration Route for DSIP, Selank, and Kisspeptin in Research

Subcutaneous vs intranasal administration for CNS-targeted research peptides: how to choose between routes for DSIP, Selank, and Kisspeptin based on molecular size, brain access, pharmacokinetics, and the published literature.

May 5, 2026

Can I Still Buy Compounded Tirzepatide? (2026 Research Context)

FDA restricted compounded tirzepatide for human use when the shortage ended. The Research Use Only research peptide channel for tirzepatide (GLP-2 TZ) operates under entirely separate regulations.

May 5, 2026

For Research Use Only. Afamelanotide and Melanotan I are intended exclusively for in vitro and preclinical research as supplied by Midwest Peptide. They are not approved for human use by Midwest Peptide, are not sold as drugs or medical products, and should never be administered to humans or to animals outside of an authorized research protocol. The clinical research literature discussed in this article is presented for research and educational purposes only.

What Is Erythropoietic Protoporphyria?

Erythropoietic protoporphyria (EPP) is a rare genetic condition caused by mutations in the ferrochelatase gene (FECH) that result in reduced enzyme activity in the heme biosynthesis pathway. The reduced ferrochelatase activity leads to accumulation of protoporphyrin IX in red blood cells and other tissues, since this molecule is the substrate for ferrochelatase and cannot be efficiently converted to heme when the enzyme is deficient.

Protoporphyrin IX is a photosensitizing molecule that absorbs visible light and reactive oxygen species in the presence of oxygen. When sunlight penetrates the skin and reaches tissues containing accumulated protoporphyrin IX, the photosensitizer is activated and produces reactive oxygen species that damage cellular components, leading to the painful photosensitive reactions characteristic of EPP. The wavelengths of visible light most relevant to the EPP photosensitive reaction are in the violet to blue range, which can penetrate through clothing and window glass that block ultraviolet light.

The clinical research base on EPP includes characterization of the genetic basis of the condition, the cellular mechanisms of the photosensitive reaction, and the search for interventions that could reduce the impact of EPP on affected individuals. Afamelanotide research in EPP is part of this broader clinical research effort.

The Rationale for Afamelanotide Research in EPP

The clinical research interest in afamelanotide for EPP arose from the recognition that increased melanin content in the skin could provide some degree of protection against the photosensitive reaction. The mechanism is straightforward at a conceptual level: melanin in the skin can absorb visible light photons before they reach tissues containing protoporphyrin IX, reducing the activation of the photosensitizer and the resulting tissue damage.

Eumelanin in particular is effective at absorbing visible light across a broad range of wavelengths, including the violet to blue wavelengths most relevant to EPP photosensitivity. Increasing eumelanin content in the skin through MC1R activation could therefore provide a way to reduce the severity of photosensitive reactions in EPP patients without requiring complete avoidance of light exposure.

This conceptual framework motivated clinical research on afamelanotide in EPP, which is one of the more chemically defined examples of using a melanocortin receptor agonist to address a specific clinical research question. The clinical research has been conducted by various research groups internationally, providing a substantial body of published findings on this application.

Published Clinical Research Findings

The published clinical research literature on afamelanotide in EPP includes multiple clinical trials that have characterized its effects on photosensitivity endpoints in EPP patients. These trials have used various endpoints including time to onset of phototoxic symptoms after sun exposure, severity of phototoxic reactions, quality of life measures related to light tolerance, and other endpoints relevant to EPP research.

The general pattern in the published findings supports measurable effects of afamelanotide on photosensitivity endpoints in EPP patients in the clinical research conducted to date. The magnitude and consistency of the effects have been characterized across multiple trials, providing the published evidence base on this application.

The clinical research findings are summarized here for research and educational purposes only. Investigators interested in the specific clinical findings should consult the peer reviewed clinical literature directly. This article does not constitute medical advice or treatment recommendations of any kind.

Mechanism of Action in EPP Research

The mechanism by which afamelanotide produces its effects in EPP research involves the canonical MC1R signaling pathway in melanocytes, leading to melanogenesis and increased eumelanin content in the skin. This is the same mechanism characterized in the broader Melanotan I melanogenesis research literature, applied to the specific research question of EPP photosensitivity.

The increased eumelanin content provides photoprotection through absorption of visible light photons in the wavelengths that activate protoporphyrin IX. This reduces the amount of light energy that reaches the photosensitizer in tissues and consequently reduces the magnitude of the photosensitive reaction. The effect is graded with eumelanin content, with higher melanin levels providing greater photoprotection in research models.

For more on the underlying melanogenesis biology, see our companion article on Melanotan I melanogenesis research and pigmentation studies.

The specificity of the mechanism for MC1R activation distinguishes afamelanotide from broader melanocortin agonists in EPP research. The MC1R selectivity allows for melanogenesis effects without the broader receptor activation profile of less selective agonists, which is functionally relevant for the EPP research context.

Afamelanotide as Research Reference Compound

Beyond its specific applications in EPP clinical research, afamelanotide serves as a research reference compound for the broader literature on selective MC1R agonists. The published clinical data complement the preclinical and animal model literature on the molecule, providing a more complete research profile than is available for many other melanocortin receptor agonists.

The combination of preclinical and clinical research data makes afamelanotide one of the more thoroughly characterized melanocortin receptor agonists in the published research literature. This research base provides valuable context for investigators studying MC1R pharmacology, melanogenesis biology, and related research questions.

The afamelanotide research literature is also useful for comparative purposes when investigators are studying other melanocortin receptor agonists or when they are characterizing the broader mechanisms of melanocortin signaling. The depth of the afamelanotide research base provides a substantial reference point for these comparative analyses.

EPP Research and the Broader Photosensitivity Literature

EPP research is part of a broader literature on photosensitivity disorders and on the biological mechanisms of light-induced tissue damage. Other photosensitivity conditions include various forms of porphyria, drug-induced photosensitivity, and other genetic conditions that affect light tolerance. The research approaches developed for EPP can sometimes be applied to other photosensitivity research questions, providing a broader context for the afamelanotide research base.

The general concept of using pigmentation enhancement as a strategy for reducing light-induced damage has been explored in research contexts beyond EPP, although EPP is the most extensively studied example in the published clinical research literature. The mechanistic principles characterized in EPP research provide a foundation for thinking about other research applications of MC1R activation in photosensitivity contexts.

Open Research Questions

Several open research questions remain in the afamelanotide EPP literature. These include how the magnitude of photoprotective effects varies across individuals with different baseline pigmentation, how the time course of effects relates to the kinetics of melanogenesis in research models, and how afamelanotide compares with other potential interventions for photosensitivity research. Each of these is a legitimate research opportunity for investigators studying pigmentation-based photoprotection.

Conclusion

Afamelanotide EPP research provides one of the more developed areas of clinical research literature on melanocortin receptor agonists. The published clinical findings, the underlying mechanism involving MC1R-mediated melanogenesis, and the position of afamelanotide as one of the more thoroughly characterized MC1R selective agonists all combine to make this an important reference area for investigators studying the broader Melanotan I research literature. For investigators using MT-1 10mg as a research tool, the EPP literature provides additional context beyond the preclinical evidence base.

For more on the full Melanotan I research cluster, see the pillar overview article and the supporting articles on each major topic.

Afamelanotide and Melanotan I are supplied by Midwest Peptide for research use only and are not intended for human administration.

Explore more peer-reviewed research and laboratory guides from our science team:

All products are third-party tested with a Certificate of Analysis (COA) included. For research use only.

MT-1 10mg, 99%+ purity, COA included
MT-2 10mg, 99%+ purity, COA included
GHK-Cu 50mg, 99%+ purity, COA included

Browse All Research Peptides →

Age Verification

Afamelanotide EPP Research: Clinical Literature Review

Frequently Asked Questions

What is Melanotan I in research contexts?

What is the EPP indication for afamelanotide?

How does afamelanotide provide photoprotection in EPP?

Is Melanotan I approved for human use?

Glossary

More from the Blog

Subcutaneous vs Intranasal: Choosing an Administration Route for DSIP, Selank, and Kisspeptin in Research

Can I Still Buy Compounded Tirzepatide? (2026 Research Context)

What Is Erythropoietic Protoporphyria?

The Rationale for Afamelanotide Research in EPP

Published Clinical Research Findings

Mechanism of Action in EPP Research

Afamelanotide as Research Reference Compound

EPP Research and the Broader Photosensitivity Literature

Open Research Questions

Conclusion

Ready to Start Your Research?

Where can researchers source third-party tested Melanotan I?

What's the Cheapest Way to Get Tirzepatide (GLP-2 TZ) for Research?

Age Verification

Afamelanotide EPP Research: Clinical Literature Review

Frequently Asked Questions

What is Melanotan I in research contexts?

What is the EPP indication for afamelanotide?

How does afamelanotide provide photoprotection in EPP?

Is Melanotan I approved for human use?

Glossary

More from the Blog

Subcutaneous vs Intranasal: Choosing an Administration Route for DSIP, Selank, and Kisspeptin in Research

Can I Still Buy Compounded Tirzepatide? (2026 Research Context)

What Is Erythropoietic Protoporphyria?

The Rationale for Afamelanotide Research in EPP

Published Clinical Research Findings

Mechanism of Action in EPP Research

Afamelanotide as Research Reference Compound

EPP Research and the Broader Photosensitivity Literature

Open Research Questions

Conclusion

Related Research Articles

Explore Related Products

Ready to Start Your Research?

Where can researchers source third-party tested Melanotan I?

What's the Cheapest Way to Get Tirzepatide (GLP-2 TZ) for Research?